OSI pursuing sustained-release Macugen

OSIP partnered with PR Pharma (Fort Collins, Colo.) to develop a sustained-release formulation of Macugen pegaptanib using PR Pharma's ProPhase encapsulation technology. PR Pharma is responsible for formulation development and for preclinical and clinical manufacturing. OSIP is responsible for clinical development and has exclusive commercialization rights. PR Pharma received an undisclosed upfront payment and is eligible for milestones and royalties. ...